Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or
“Novo Integrated Sciences”), a provider of multidisciplinary
primary healthcare, welcomes Dr. Joseph M. Chalil, Dr. Michael G.
Muhonen, and Dr. Zach P. Zachariah as charter members to the
Company’s newly-formed Medical Advisory Board. This group of
world-renowned leaders within their respective medical fields
provides the Company with important insight and expertise as the
Company expands its personalized consumer engagement across all
aspects of the patient/practitioner relationship through the
integration of medical technology, advanced therapeutics, and
rehabilitative sciences.
Robert Mattacchione, the Company’s CEO and Board Chairman,
stated, “It is a true privilege to welcome Dr. Chalil, Dr. Muhonen,
and Dr. Zachariah to the Novo family as charter members of the
Medical Advisory Board. I deeply appreciate their commitment to
contributing their expertise, guidance, and shared vision as the
Company accelerates both its geographic expansion into the Americas
and further advances its model focused on shifting the
patient/practitioner relationship to the patient’s home through
ongoing advancements in both medical technology and
inter-connectivity. We believe that each member’s understanding of
the medical communities’ needs and wants coupled with their
significant insight into regulatory matters surrounding technology
application and product-based solutions will be invaluable.
Individually aligned to our model and collectively creating a voice
of significance, Novo is secure in its corporate mandate of
ensuring medical community adoption of its philosophy through the
guidance of an impressive Medical Advisory Board.”
Introducing the charter members of the
Novo Integrated Sciences Medical Advisory Board (in alphabetical
order):
Dr. Joseph M. Chalil, MD, MBA, FACHE, Chairman of the Medical
Advisory Board
Prof. Joseph M. Chalil is an author of several scientific and
research papers in international publications, is the Chairman of
the Complex Health Systems Advisory Board, H. Wayne Huizenga
College of Business and Entrepreneurship at Nova Southeastern
University in Florida, and a member of Dr. Kiran C. Patel College
of Allopathic Medicine (NSU MD) Executive Leadership Council. A
veteran of the U.S. Navy Medical Corps, he is board certified in
healthcare management. He has been awarded a Fellowship by the
American College of Healthcare Executives, an international
professional society of more than 40,000 healthcare executives who
lead hospitals, healthcare systems, and other healthcare
organizations. Additionally, Dr. Chalil is the Chairman of the
Indo-American Press Club (IAPC). He is an expert in U.S. healthcare
policy and a strong advocate for patient-centered care. A strong
proponent of providing healthcare access for everyone, Dr. Chalil's
new book Beyond the COVID-19 Pandemic: Envisioning a Better
World by Transforming the Future of Healthcare is now on
Amazon's Best Sellers List.
Dr. Michael G. Muhonen, MD
Dr. Muhonen is a renowned neurosurgeon who practices at
Children’s Hospital of Orange County. Dr. Muhonen believes in
treating all patients like family members and strives to leave
every medical situation better than how he encountered it. Dr.
Muhonen has been recognized as one of the “Best Doctors in Orange
County, California, specialty of Neurological Surgery” in Orange
Coast Magazine.
He grew up in Idaho, one in a family of ten children. Dr.
Muhonen attended Oral Roberts University in Tulsa, Oklahoma, where
he graduated in 1983, before attending medical school. He then
completed a residency in neurosurgery, at the University of Iowa
Hospitals in Iowa City, Iowa in 1993. In 1995, he became the
director of neurosurgery at Children's Hospital of Orange County in
Orange, California. He held this position until 2020. During his
tenure as chairman, the neurosurgical case volume grew from under
100 cases a year to over 800 cases annually.
Dr. Muhonen has maintained a committed interest in the science
of neurological disorders. He is an Associate Clinical Professor at
the University of California Irvine, College of Medicine, with
ongoing research in hydrocephalus, cerebral palsy, and cerebral
blood flow. Dr. Muhonen is board-certified by the American Board of
Neurological Surgeons, the American Board of Pediatric Neurological
Surgery, and is a Fellow of the American Academy of Pediatrics. He
won the Galbraith Award in 1991, for outstanding cerebrovascular
research, from the Congress of Neurological Surgeons/American
Association of Neurological Surgeons, Joint Section Cerebrovascular
Surgery. He currently oversees a hydrocephalus research lab and has
led multiple clinical trials at Children’s Hospital of Orange
County. Dr. Muhonen serves on the Board of the Hydrocephalus
Association, and previously served on the Boards of the
Hydrocephalus Foundation, and the Children’s Hospital of Orange
County Foundation. He has been a medical advisor to Medtronic,
Alcyone, Anuncia, Codman and Integra LifeSciences.
Dr. Zach P. Zachariah, MD
Dr. Zach Zachariah is the Medical Director of UHealth
Cardiology, Fort Lauderdale and on the Clinical Faculty of the
University of Miami School of Medicine. He is also the President of
Fort Lauderdale Heart Institute in Fort Lauderdale, Florida. He has
been practicing interventional cardiology at Holy Cross Hospital
since 1976 and was its Director of Cardiovascular Services until
2010. Dr. Zachariah is board-certified in internal medicine and
cardiology and specializes in cardiology, cardiac catheterization,
and interventional cardiology and has performed more than 30,000
heart catheterizations and interventional procedures in Broward
County, Florida. He has also co-authored several scientific papers
in National Journal and participated in various clinical
trials.
Currently, he serves as the Chairman of the Florida Board of
Medicine, and as a member of the National Advisory Council of the
National Heart, Lung and Blood Institute of the National Institutes
of Health. He also serves as a member of the Board of Trustees of
Nova Southeastern University, a member of its executive committee
and as the Chairman of the Research and Technology Transfer
Committee. He also serves as a member of the Council of 100 in
Florida and as a Board member of the National Board of ExcelinED in
Action. He also serves as a board member of Geo Toll Inc. He
currently serves on the Scientific Advisory Committee of BioSig
Technologies, Inc. (NASDAQ).
He had served on the Florida Board of Governors of the State
University system in Florida from 2003 to 2010 and from 2017 to May
2019. He has also served on the member of National Advisory Council
of the National Heart, Lung and Blood Institute at the National
Institutes of Health from 1990 to 1993 and as a member of the U.S.
delegation to the World Health Organization in Geneva, Switzerland.
He also served as Chairman of the Florida Board of Medicine from
1990-1992, 2000-2001 and 2013-2014. He also served as a member of
the President’s Advisory Commission on Asian Americans and Pacific
Islanders appointed by President George W. Bush in 2001.
He received his medical degree from the Armed Forces Medical
College in India, and then completed his residency at St. Joseph’s
Hospital and Medical Center in Paterson, New Jersey. He also
completed a fellowship in interventional cardiology at the
Cleveland Clinic Educational Foundation in Cleveland, Ohio.
Dr. Zachariah holds numerous awards, including the Ellis Island
American Legend Award, the Child Advocate of the Year Award, Father
of the Year Award, Spirit of Life Award from City of Hope, the
Golden Heart Award from the American Heart Association, Ellis
Island Medal of Honor, Freedom Foundation Medal of Honor from the
Freedom Foundation at Valley Forge, and Sister Innocent Hughes
Award for his contribution to health and science by Holy Cross
Hospital. In the past, three Florida Governors and the Cabinet have
declared “Zachariah P. Zachariah Day” in Florida five times.
About Novo Integrated Sciences,
Inc.
Novo Integrated Sciences, Inc. owns Canadian and U.S.
subsidiaries which deliver, or intend to deliver, multidisciplinary
primary health care related services and products through the
integration of medical technology, advanced therapeutics and
rehabilitative science. Our clinicians and practitioners are not
authorized to practice primary care medicine and they are not
medically licensed to prescribe pharmaceutical based product
solutions.
Currently, the Company’s revenue is generated solely through our
Canadian subsidiary, Novo Healthnet Limited (“NHL”). NHL’s team of
multidisciplinary primary health care clinicians and practitioners
provide assessment, diagnosis, treatment, pain management,
rehabilitation, education and primary prevention for a wide array
of orthopedic, musculoskeletal, sports injury, and neurological
conditions across various demographics including pediatric, adult,
and geriatric populations through NHL’s 16 corporate-owned clinics,
a contracted network of affiliate clinics, and eldercare related
long-term care homes, retirement homes, and community-based
locations in Canada.
Our specialized multidisciplinary primary health care services
include, but are not limited to, physiotherapy, chiropractic care,
manual/manipulative therapy, occupational therapy, eldercare,
massage therapy (including pre- and post-partum), acupuncture and
functional dry needling, chiropody, stroke and traumatic brain
injury/neurological rehabilitation, kinesiology, vestibular
therapy, concussion management and baseline testing, trauma
sensitive yoga and meditation for concussion-acquired brain injury
and occupational stress-PTSD, women’s pelvic health programs,
sports medicine therapy, assistive devices, dietitian, holistic
nutrition, fall prevention education, sports team conditioning
programs including event and game coverage, and private personal
training.
We believe that “decentralizing” healthcare, through the
integration of medical technology and interconnectivity offers an
essential solution to the fundamental transformation of healthcare
delivery. Specific to non-critical care, ongoing advancements in
both medical technology and inter-connectivity are allowing for a
shift of the patient/practitioner relationship to the patient’s
home and away from on-site visits to primary medical centers with
mass-services. This acceleration of “ease-of-access” in the
patient/practitioner interaction for non-critical care diagnosis
and subsequent treatment minimizes the degradation of non-critical
health conditions to critical conditions as well as allowing for
more cost-effective healthcare distribution.
For more information concerning Novo Integrated Sciences, please
visit www.novointegrated.com. For more information on NHL, please
visit www.novohealthnet.com.
Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. All statements other than statements of historical facts
included in this press release are forward-looking statements. In
some cases, forward-looking statements can be identified by words
such as "believe," “intend,” "expect," "anticipate," "plan,"
"potential," "continue" or similar expressions. Such
forward-looking statements include risks and uncertainties, and
there are important factors that could cause actual results to
differ materially from those expressed or implied by such
forward-looking statements. These factors, risks and uncertainties
are discussed in Novo Integrated Sciences' filings with the
Securities and Exchange Commission. Investors should not place any
undue reliance on forward-looking statements since they involve
known and unknown, uncertainties and other factors which are, in
some cases, beyond Novo Integrated Sciences' control which could,
and likely will, materially affect actual results, levels of
activity, performance or achievements. Any forward-looking
statement reflects Novo Integrated Sciences' current views with
respect to future events and is subject to these and other risks,
uncertainties and assumptions relating to operations, results of
operations, growth strategy and liquidity. Novo Integrated Sciences
assumes no obligation to publicly update or revise these
forward-looking statements for any reason, or to update the reasons
actual results could differ materially from those anticipated in
these forward-looking statements, even if new information becomes
available in the future. The contents of any website referenced in
this press release are not incorporated by reference herein.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210422005313/en/
Chris David, President Novo Integrated Sciences, Inc.
chris.david@novointegrated.com (206) 617-9797
Novo Integrated Sciences (NASDAQ:NVOS)
過去 株価チャート
から 6 2024 まで 7 2024
Novo Integrated Sciences (NASDAQ:NVOS)
過去 株価チャート
から 7 2023 まで 7 2024